Genetic insight into sick sinus syndrome. Is there a pill for it or how far are we on the translational road to personalized medicine?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Efficacy and safety of Lingbao Huxin Dan in the treatment of sick sinus syndrome: a randomized, single-blind, placebo-controlled, crossover trial.Frontiers in cardiovascular medicine · 2026
   Trial
2. Compound Tongyang Fumai decoction improves quality of life in sick sinus syndrome: a randomized controlled study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024
   Trial
3. Trends in research on sick sinus syndrome: A bibliometric analysis from 2000 to 2022.Frontiers in cardiovascular medicine · 2022
   Review

Corrections and comments

• Comment on
  Genetic insight into sick sinus syndrome.2021

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as